The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 **FORM D**

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB Number: 3235-0076

Estimated average burden
hours per response: 4.00

1. Issuer's Identity			
CIK (Filer ID Number)	Previous	X None	Entity Type
	Names	ATTORIO	
0001446159			X Corporation
Name of Issuer			Limited Partnership
BioDrain Medical, Inc.			Limited Liability Company
Jurisdiction of Incorporation/Org	ganization		General Partnership
MINNESOTA			Business Trust
Year of Incorporation/Organizat	lion		Other (Specify)
X Over Five Years Ago			Other (Specify)
Within Last Five Years (Spe	ecify Year)		
Yet to Be Formed			
2. Principal Place of Business	and Contact Information		
Name of Issuer			
BioDrain Medical, Inc.			
Street Address 1		Street Address 2	
2060 Centre Pointe Blvd.		Suite 7	
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
Mendota Heights	MN	55120	(651)389-4800
3. Related Persons			
Last Name	First Name		Middle Name
Davidson	Kevin		R.
Street Address 1	Street Address 2		
2060 Centre Pointe Blvd., Suite 7	•		
City	State/Province/Co	untry	ZIP/PostalCode
Mendota Heights	MN		55120
Relationship: X Executive Offi	icer X Director Promoter		
Clarification of Response (if Neo	cessary):		
Mr. Davidson serves as the Preside	ent, Chief Executive Officer, Chie	f Financial Officer and D	Director.
Last Name	First Name		Middle Name
Gadbaw	Lawrence		W.
Street Address 1	Street Address 2		
2060 Centre Pointe Blvd., Suite 7	•		
City	State/Province/Co	untry	ZIP/PostalCode
Mendota Heights	MN		55120
Relationship: Executive Offi	cer X Director Promoter		
Clarification of Response (if Neo	cessary):		
Mr. Gadbaw serves as the Chairma	n of the Board of Directors.		
Last Name	First Name		Middle Name
Ruwe	Chad		A.

Street Address 1	Street Address 2	
2060 Centre Pointe Blvd., Suite 7		
City	State/Province/Country	ZIP/PostalCode
Mendota Heights	MN	55120
Relationship: X Executive Officer X Dir	ector Promoter	
Clarification of Response (if Necessary):		
Mr. Ruwe serves as the Chief Operating Offic	er and Director.	
Last Name	First Name	Middle Name
Doerfert	Kirsten	
Street Address 1	Street Address 2	
2060 Centre Pointe Blvd., Suite 7		
City	State/Province/Country	ZIP/PostalCode
Mendota Heights	MN	55120
Relationship: X Executive Officer Dir	ector Promoter	
Clarification of Response (if Necessary):		
Ms. Doerfert serves as the Vice President of S	ales and Marketing.	
Last Name	First Name	Middle Name
Dauwalter	James	E.
Street Address 1	Street Address 2	
2060 Centre Pointe Blvd., Suite 7		
City	State/Province/Country	ZIP/PostalCode
Mendota Heights	MN	55120
Relationship: Executive Officer X Dir	ector Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Morawetz	Peter	L.
Street Address 1	Street Address 2	
2060 Centre Pointe Blvd., Suite 7		
City	State/Province/Country	ZIP/PostalCode
Mendota Heights	MN	55120
Relationship: Executive Officer X Dir	ector Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
McGoldrick	Thomas	J.
Street Address 1	Street Address 2	
2060 Centre Pointe Blvd., Suite 7		
City	State/Province/Country	ZIP/PostalCode
Mendota Heights	MN	55120
Relationship: Executive Officer X Dir	ector Promoter	
Clarification of Response (if Necessary):	_	
	F:	
Last Name	First Name	Middle Name
Reding	Andrew	Р.
Street Address 1	Street Address 2	
2060 Centre Pointe Blvd., Suite 7	State/Drovings/Country	ZID/DactalCode
City	State/Province/Country	ZIP/PostalCode
Mendota Heights	MN	55120
Relationship: Executive Officer X Dir	ector Promoter	
Clarification of Response (if Necessary):		

Last Name	First Name	Middle Name
Shuler Street Address 1	Alan Street Address 2	
2060 Centre Pointe Blvd., Suite 7	Street Address 2	
City	State/Province/Country	ZIP/PostalCode
Mendota Heights	MN	55120
Relationship: X Executive Officer Direct	ctor Promoter	
Clarification of Response (if Necessary):		
Mr. Shuler serves as the Corporate Secretary.		
4. Industry Group		
Agriculture	Health Care	Retailing
Banking & Financial Services	Biotechnology	Restaurants
Commercial Banking	Health Insurance	Technology
Insurance		
Investing	Hospitals & Physicians	Computers
Investment Banking	Pharmaceuticals	Telecommunications
Pooled Investment Fund	X Other Health Care	Other Technology
Is the issuer registered as	Manufacturing	Travel
an investment company under	Real Estate	Airlines & Airports
the Investment Company Act of 1940?	Commercial	
☐Yes ☐ No	Construction	Lodging & Conventions
Other Banking & Financial Services		Tourism & Travel Services
Other Banking & Financial Services	REITS & Finance	Other Travel
Business Services	Residential	Other
Energy		Otto
Coal Mining	Other Real Estate	
Electric Utilities		
Energy Conservation		
Environmental Services		
Oil & Gas		
Other Energy		
Other Energy		
5. Issuer Size		
Revenue Range OR	Aggregate Net Asset V	alue Range
X No Revenues	No Aggregate Net A	
\$1 - \$1,000,000	\$1 - \$5,000,000	
\$1,000,001 - \$5,000,000	\$5,000,001 - \$25,000	0,000

\$5,000,001 - \$25,000,000	\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000	\$50,000,001 - \$100,000,000
Over \$100,000,000	Over \$100,000,000
Decline to Disclose	Decline to Disclose
Not Applicable	Not Applicable
6. Federal Exemption(s) and Exclusion(s) Claims	ed (select all that apply)
Rule 504(b)(1) (not (i), (ii) or (iii))	Rule 505
Rule 504 (b)(1)(i)	X Rule 506
Rule 504 (b)(1)(ii)	Securities Act Section 4(5)
Rule 504 (b)(1)(iii)	Investment Company Act Section 3(c)
	Section 3(c)(1) Section 3(c)(9)
	Section 3(c)(2) Section 3(c)(10)
	Section 3(c)(3) Section 3(c)(11)
	Section 3(c)(4) Section 3(c)(12)
	Section 3(c)(5) Section 3(c)(13)
	Section 3(c)(6) Section 3(c)(14)
	Section 3(c)(7)
7. Type of Filing	
X New Notice Date of First Sale 2008-06-11	First Sale Yet to Occur
Amendment	
8. Duration of Offering	
Does the Issuer intend this offering to last more that	an one year? Yes X No
9. Type(s) of Securities Offered (select all that ap	ply)
X Equity	Pooled Investment Fund Interests
Debt	Tenant-in-Common Securities
Option, Warrant or Other Right to Acquire Anoth	
Security to be Acquired Upon Exercise of Option Right to Acquire Security	
10. Business Combination Transaction	
Is this offering being made in connection with a bus merger, acquisition or exchange offer?	siness combination transaction, such as a Yes X No
Clarification of Response (if Necessary):	
11. Minimum Investment	
Minimum investment accepted from any outside inv	vestor \$3,000 USD
12. Sales Compensation	
Recipient	Recipient CRD Number X None
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number \overline{X} None
Street Address 1	Street Address 2
City	State/Province/Country ZIP/Postal Code
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	Il States Foreign/non-US

13. Offering and Sales Amounts
Total Offering Amount \$2,485,443 USD or Indefinite
Total Amount Sold \$1,593,502 USD
Total Remaining to be Sold \$891,941 USD or Indefinite
Clarification of Response (if Necessary):
14. Investors
Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
15. Sales Commissions & Finder's Fees Expenses
Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions \$0 USD Estimate
Finders' Fees \$0 USD Estimate
Clarification of Response (if Necessary):
16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
\$268,500 USD Estimate
Clarification of Response (if Necessary):
Executive officer salaries and board chairman fees.
Signature and Submission
Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to

file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- · Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disgualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
BioDrain Medical, Inc.	/s/ Kevin R. Davidson	Kevin R. Davidson	President, Chief Executive Officer & Chief Financial Officer	2009-11-03

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.